Orally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase. Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone reabsorption in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon et al.
Lowering bone mineral affinity of bisphosphonates as a therapeutic stragey to optimize skeletal tumor growth inhibition in vivo.
Fournier et al.
Cancer Res., 2008;68:8945
Bisphosphonates in cancer therapy.
Stressing et al.
Cancer Letts., 2007;257:16